STEPHEN DAVIS - 23 Feb 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
23 Feb 2022
Net transactions value
-$93,486
Form type
4
Filing time
25 Feb 2022, 16:40:50 UTC
Previous filing
10 Jan 2022
Next filing
07 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +10,945 +19% $0.000000 69,661 23 Feb 2022 Direct
transaction ACAD Common Stock Sale $93,486 -3,928 -5.6% $23.80 65,733 23 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 +10,945 +50% $0.000000 32,837 23 Feb 2022 Common Stock 10,945 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning February 23 2022.